{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:46:41Z","timestamp":1770425201210,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Thymomas are one of the most common neoplasms of the anterior mediastinum with limited therapeutic options, particularly in advanced stages. The molecular profiles of these tumors remain poorly investigated. This study aims to evaluate the expression of programmed death ligand 1 (PD-L1) in a selected cohort of intentionally curative resected thymomas and evaluate a possible relationship with the risk of recurrence. This retrospective bicentric study analyzed a group of patients who underwent complete thymectomy with curative intent. PD-L1 expression was assessed through immunohistochemistry using the Ventana PD-L1 assay. PD-L1 expression was assessed as low if &lt;50% or high when \u226550%. The Kaplan\u2013Meier method and Cox regression analysis were performed to evaluate a possible relationship between PD-L1 expression and disease-free survival. High PD-L1 expression was observed in 46.2% of patients. Overexpression of this protein was significantly associated with aggressive (B2\/B3) thymomas histotypes (p&lt;0.001). During follow-up period, 12\/52 patients developed recurrence. High PD-L1 expression correlated with reduced disease-free survival with Kaplan-Meier method (p&lt;0.001). Furthermore, PD-L1 expression more than 50% resulted to be related to a worse prognosis at multivariable Cox regression analysis (hazard ratio 5.4, 95% confidence interval 1.5\u201316.9, p=0.028) together with histology (p=0.044) and Masaoka-Koga stage (p=0.026). The elevated expression of PD-L1, particularly in aggressive thymoma subtypes, underscores its potential as a prognostic biomarker. These findings support the need for further research to explore the potential of immunotherapy in treating these rare malignancies.<\/jats:p>","DOI":"10.1007\/s13304-025-02242-w","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T01:32:56Z","timestamp":1748136776000},"page":"1335-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Programmed death-ligand 1 expression in surgically resected thymomas"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7188-5107","authenticated-orcid":false,"given":"Luca","family":"Frasca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1048-6625","authenticated-orcid":false,"given":"Antonio","family":"Sarubbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-1684","authenticated-orcid":false,"given":"Filippo","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-5251","authenticated-orcid":false,"given":"Valentina","family":"Marziali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7409-8470","authenticated-orcid":false,"given":"Alexandro","family":"Patirelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-6714","authenticated-orcid":false,"given":"Pierfilippo","family":"Crucitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-3175","authenticated-orcid":false,"given":"Vincenzo","family":"Ambrogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"1","key":"2242_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","volume":"44","author":"WK de Jong","year":"2008","unstructured":"de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ (2008) \u201cThymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy,\u201d (in eng). Eur J Cancer 44(1):123\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2007.11.004","journal-title":"Eur J Cancer"},{"issue":"4","key":"2242_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/BF02662474","volume":"54","author":"Y Kojima","year":"2006","unstructured":"Kojima Y, Ito H, Hasegawa S, Sasaki T, Inui K (2006) \u201cResected invasive thymoma with multiple endocrine neoplasia type 1,\u201d (in eng). Jpn J Thorac Cardiovasc Surg 54(4):171\u2013173. https:\/\/doi.org\/10.1007\/BF02662474","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"issue":"Suppl 5","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG (2015) \u201cThymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,\u201d (in eng). Ann Oncol 26(Suppl 5):v40-55. https:\/\/doi.org\/10.1093\/annonc\/mdv277","journal-title":"Ann Oncol"},{"issue":"8","key":"2242_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182665","volume":"12","author":"KC Arbour","year":"2017","unstructured":"Arbour KC et al (2017) \u201cExpression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors,\u201d (in eng). PLoS ONE 12(8):e0182665. https:\/\/doi.org\/10.1371\/journal.pone.0182665","journal-title":"PLoS ONE"},{"key":"2242_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.lungcan.2020.04.038","volume":"145","author":"S Ishihara","year":"2020","unstructured":"Ishihara S et al (2020) \u201cProgrammed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses,\u201d (in eng). Lung Cancer 145:40\u201347. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.038","journal-title":"Lung Cancer"},{"key":"2242_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100392","author":"Y He","year":"2021","unstructured":"He Y, Ramesh A, Gusev Y, Bhuvaneshwar K, Giaccone G (2021) \u201cMolecular predictors of response to pembrolizumab in thymic carcinoma,\u201d (in eng). Cell Rep Med. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100392","journal-title":"Cell Rep Med"},{"issue":"3","key":"2242_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G et al (2018) \u201cPembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study,\u201d (in eng). Lancet Oncol 19(3):347\u2013355. https:\/\/doi.org\/10.1016\/S1470-2045(18)30062-7","journal-title":"Lancet Oncol"},{"key":"2242_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071369","author":"A Rajan","year":"2024","unstructured":"Rajan A, Sivapiromrat AK, McAdams MJ (2024) \u201cImmunotherapy for Thymomas and Thymic carcinomas: current status and future directions,\u201d (in eng). Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16071369","journal-title":"Cancers (Basel)"},{"key":"2242_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3389\/fonc.2019.01055","volume":"9","author":"JS Song","year":"2019","unstructured":"Song JS, Kim D, Kwon JH, Kim HR, Choi CM, Jang SJ (2019) \u201cClinicopathologic significance and immunogenomic analysis of programmed death-ligand 1 (PD-L1) and programmed death 1 (pd-1) expression in thymic epithelial tumors,\u201d (in eng). Front Oncol 9:1055. https:\/\/doi.org\/10.3389\/fonc.2019.01055","journal-title":"Front Oncol"},{"key":"2242_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235574","author":"M Perrino","year":"2023","unstructured":"Perrino M et al (2023) \u201cThymic epithelial tumor and immune system: the role of immunotherapy,\u201d (in eng). Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15235574","journal-title":"Cancers (Basel)"},{"key":"2242_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","volume":"104","author":"M Tiseo","year":"2017","unstructured":"Tiseo M et al (2017) \u201cAnalysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs),\u201d (in eng). Lung Cancer 104:24\u201330. https:\/\/doi.org\/10.1016\/j.lungcan.2016.12.005","journal-title":"Lung Cancer"},{"key":"2242_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020610","author":"MC Ambrogi","year":"2024","unstructured":"Ambrogi MC et al (2024) \u201cTNM staging system in thymoma: a critical appraisal?,\u201d (in eng). J Clin Med. https:\/\/doi.org\/10.3390\/jcm13020610","journal-title":"J Clin Med"},{"key":"2242_CR13","doi-asserted-by":"publisher","first-page":"5830547","DOI":"10.1155\/2018\/5830547","volume":"2018","author":"Y Chen","year":"2018","unstructured":"Chen Y, Zhang Y, Chai X, Gao J, Chen G, Zhang W (2018) \u201cCorrelation between the expression of PD-L1 and clinicopathological features in patients with thymic epithelial tumors,\u201d (in eng). Biomed Res Int 2018:5830547. https:\/\/doi.org\/10.1155\/2018\/5830547","journal-title":"Biomed Res Int"},{"issue":"1","key":"2242_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5761\/atcs.oa.16-00205","volume":"23","author":"A Kitami","year":"2017","unstructured":"Kitami A et al (2017) \u201cThe usefulness of positron-emission tomography findings in the management of anterior mediastinal tumors,\u201d (in eng). Ann Thorac Cardiovasc Surg 23(1):26\u201330. https:\/\/doi.org\/10.5761\/atcs.oa.16-00205","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"2242_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivac167","author":"E Voulaz","year":"2022","unstructured":"Voulaz E et al (2022) \u201cThymomectomy versus complete thymectomy in early-stage non-myasthenic thymomas: a multicentric propensity score-matched study,\u201d (in eng). Interact Cardiovasc Thorac Surg. https:\/\/doi.org\/10.1093\/icvts\/ivac167","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"3","key":"2242_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/1759-7714.14258","volume":"13","author":"L Frasca","year":"2022","unstructured":"Frasca L et al (2022) \u201cUniportal video-assisted thoracic surgery approach for simultaneous lung cancer and thymic carcinoma: case report and literature review,\u201d (in eng). Thorac Cancer 13(3):489\u2013493. https:\/\/doi.org\/10.1111\/1759-7714.14258","journal-title":"Thorac Cancer"},{"issue":"11","key":"2242_CR17","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r","volume":"48","author":"A Masaoka","year":"1981","unstructured":"Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) \u201cFollow-up study of thymomas with special reference to their clinical stages,\u201d (in eng). Cancer 48(11):2485\u20132492. https:\/\/doi.org\/10.1002\/1097-0142(19811201)48:11%3c2485::aid-cncr2820481123%3e3.0.co;2-r","journal-title":"Cancer"},{"key":"2242_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-019-0177-8","volume":"7","author":"I Rouquette","year":"2019","unstructured":"Rouquette I et al (2019) \u201cImmune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1,\u201d (in eng). Biomark Res 7:28. https:\/\/doi.org\/10.1186\/s40364-019-0177-8","journal-title":"Biomark Res"},{"issue":"3","key":"2242_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/NT.0000000000000092","volume":"50","author":"FQ Nuttall","year":"2015","unstructured":"Nuttall FQ (2015) \u201cBody mass index: obesity, BMI, and health: a critical review,\u201d (in eng). Nutr Today 50(3):117\u2013128. https:\/\/doi.org\/10.1097\/NT.0000000000000092","journal-title":"Nutr Today"},{"issue":"10","key":"2242_CR20","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/cncr.21433","volume":"104","author":"TC Mineo","year":"2005","unstructured":"Mineo TC et al (2005) Long-term disease-free survival of patients with radically resected thymomas. Relevance of cell cycle protein expression. Cancer 104(10):2063\u20132071. https:\/\/doi.org\/10.1002\/cncr.21433","journal-title":"Cancer"},{"issue":"9 Suppl 2","key":"2242_CR21","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","volume":"9","author":"A Rajan","year":"2014","unstructured":"Rajan A, Girard N, Marx A (2014) \u201cState of the art of genetic alterations in thymic epithelial tumors,\u201d (in eng). J Thorac Oncol 9(9 Suppl 2):S131\u2013S136. https:\/\/doi.org\/10.1097\/JTO.0000000000000298","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2242_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","volume":"19","author":"DS Ettinger","year":"2021","unstructured":"Ettinger DS et al (2021) \u201cNCCN Guidelines Insights: non-small cell lung cancer, version 2.2021,\u201d (in eng). J Natl Compr Canc Netw 19(3):254\u2013266. https:\/\/doi.org\/10.6004\/jnccn.2021.0013","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2242_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/his.13936","volume":"75","author":"T Sakane","year":"2019","unstructured":"Sakane T et al (2019) \u201cA mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A\/B3,\u201d (in eng). Histopathology 75(5):755\u2013766. https:\/\/doi.org\/10.1111\/his.13936","journal-title":"Histopathology"},{"issue":"11","key":"2242_CR24","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1111\/1759-7714.13590","volume":"11","author":"HM Koh","year":"2020","unstructured":"Koh HM, Jang BG, Lee HJ, Hyun CL (2020) \u201cPrognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: a meta-analysis,\u201d (in eng). Thorac Cancer 11(11):3086\u20133098. https:\/\/doi.org\/10.1111\/1759-7714.13590","journal-title":"Thorac Cancer"},{"issue":"3","key":"2242_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK et al (2015) \u201cDiffuse high intensity PD-L1 staining in thymic epithelial tumors,\u201d (in eng). J Thorac Oncol 10(3):500\u2013508. https:\/\/doi.org\/10.1097\/JTO.0000000000000429","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2242_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA et al (2003) \u201cBlockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production,\u201d (in eng). J Immunol 170(3):1257\u20131266. https:\/\/doi.org\/10.4049\/jimmunol.170.3.1257","journal-title":"J Immunol"},{"issue":"2","key":"2242_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","volume":"88","author":"Y Katsuya","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K (2015) \u201cImmunohistochemical status of PD-L1 in thymoma and thymic carcinoma,\u201d (in eng). Lung Cancer 88(2):154\u2013159. https:\/\/doi.org\/10.1016\/j.lungcan.2015.03.003","journal-title":"Lung Cancer"},{"key":"2242_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","volume":"60","author":"AM Marchevsky","year":"2017","unstructured":"Marchevsky AM, Walts AE (2017) \u201cPD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus,\u201d (in eng). Hum Pathol 60:16\u201323. https:\/\/doi.org\/10.1016\/j.humpath.2016.09.023","journal-title":"Hum Pathol"},{"issue":"18","key":"2242_CR29","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","volume":"22","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S et al (2016) \u201cPrognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma,\u201d (in eng). Clin Cancer Res 22(18):4727\u20134734. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0434","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2242_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","volume":"101","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S et al (2016) \u201cClinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma,\u201d (in eng). Ann Thorac Surg 101(4):1361\u20131369. https:\/\/doi.org\/10.1016\/j.athoracsur.2015.10.044","journal-title":"Ann Thorac Surg"},{"issue":"12","key":"2242_CR31","doi-asserted-by":"publisher","first-page":"7553","DOI":"10.21037\/jtd-19-3703","volume":"12","author":"S Yokoyama","year":"2020","unstructured":"Yokoyama S, Miyoshi H (2020) \u201cComparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma,\u201d (in eng). J Thorac Dis 12(12):7553\u20137560. https:\/\/doi.org\/10.21037\/jtd-19-3703","journal-title":"J Thorac Dis"},{"issue":"24","key":"2242_CR32","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho J et al (2019) \u201cPembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial,\u201d (in eng). J Clin Oncol 37(24):2162\u20132170. https:\/\/doi.org\/10.1200\/JCO.2017.77.3184","journal-title":"J Clin Oncol"},{"issue":"4","key":"2242_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100188","volume":"6","author":"F Conforti","year":"2021","unstructured":"Conforti F et al (2021) \u201cClinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian association of medical oncology (AIOM),\u201d (in eng). ESMO Open 6(4):100188. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100188","journal-title":"ESMO Open"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-025-02242-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:22:31Z","timestamp":1757438551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-025-02242-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1007\/s13304-025-02242-w","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki with permission of Internal Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Informed consent for the use of personal data for scientific reasons was obtained from all subjects involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}